iifl-logo

Glenmark Pharmaceuticals Ltd Share Price

1,636.7
(-0.15%)
Jun 20, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,633.9
  • Day's High1,645.5
  • 52 Wk High1,830.95
  • Prev. Close1,639.2
  • Day's Low1,625
  • 52 Wk Low 1,199.3
  • Turnover (lac)18,931.23
  • P/E26.48
  • Face Value1
  • Book Value871.05
  • EPS61.81
  • Mkt. Cap (Cr.)46,187.81
  • Div. Yield0.15
View All Historical Data
Loading...
  • Open1,639.6
  • Day's High1,649.2
  • Spot1,636.7
  • Prev. Close1,637.6
  • Day's Low1,628.4
  • ViewShort Covering
  • Market Lot325
  • OI(Chg %)-4,53,050 (-5.7%)
  • Roll Over%0.25
  • Roll Cost1.03
  • Traded Vol.16,40,275 (84%)
View More Futures

Glenmark Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,633.9

Prev. Close

1,639.2

Turnover(Lac.)

18,931.23

Day's High

1,645.5

Day's Low

1,625

52 Week's High

1,830.95

52 Week's Low

1,199.3

Book Value

871.05

Face Value

1

Mkt Cap (₹ Cr.)

46,187.81

P/E

26.48

EPS

61.81

Divi. Yield

0.15

Glenmark Pharmaceuticals Ltd Corporate Action

12 May 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

30 Aug 2024

12:00 AM

AGM

Announcement Date: 30 Aug, 2024

arrow

Glenmark Pharmaceuticals Ltd NEWS AND UPDATE

Top Stocks for Today - 26th May 2025
26 May 2025|06:34 AM

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.

Read More
Glenmark Pharma’s cancer drug receive FDA ‘fast track’ status
6 May 2025|09:31 AM

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

Read More
Glenmark Pharma Appoints Anurag Mantri as New CFO
7 Apr 2025|12:21 PM

The reshuffle comes after VS Mani, the company's current chief, announced early retirement; he will officially retire as chief on May 26, 2025 after an eight-year career with the company.

Read More
Glenmark Gets USFDA Nod for Olopatadine Ophthalmic Solution
23 Mar 2025|11:40 AM

This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.

Read More
Glenmark Expands US Portfolio with Acetylcysteine Injection Launch
3 Mar 2025|09:57 PM

Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glenmark Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

21 Jun, 2025|10:58 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 46.64%

Foreign: 0.00%

Indian: 46.64%

Non-Promoter- 37.79%

Institutions: 37.79%

Non-Institutions: 15.55%

Custodian: 0.00%

Share Price

Glenmark Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

28.22

28.22

28.22

28.22

Preference Capital

0

0

0

0

Reserves

22,942.4

17,849.25

16,710.37

14,781.29

Net Worth

22,970.62

17,877.47

16,738.59

14,809.51

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

7,567.93

6,712.63

6,403.23

7,989.23

yoy growth (%)

12.74

4.83

-19.85

30.64

Raw materials

-2,999.45

-2,665.99

-2,378.59

-2,425.49

As % of sales

39.63

39.71

37.14

30.35

Employee costs

-1,107.39

-1,072.32

-1,021.92

-914.47

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1,869.86

1,516.09

1,218.82

2,789.34

Depreciation

-150.81

-138.53

-118.2

-104.93

Tax paid

-294.31

-180.09

-204.47

-412.28

Working capital

463.74

-1,507.52

-180.36

1,492.86

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

12.74

4.83

-19.85

30.64

Op profit growth

44.93

-3.21

-53.51

64.2

EBIT growth

20.49

25.73

-52.08

65.02

Net profit growth

21.77

33.53

-52.61

44.21

View Ratios
Particulars (Rupees in Crores.)Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

13,145.84

11,635.46

11,431.94

12,174.2

10,806.03

Excise Duty

0

0

0

0

0

Net Sales

13,145.84

11,635.46

11,431.94

12,174.2

10,806.03

Other Operating Income

175.9

177.64

151.3

130.71

137.9

Other Income

113.72

1,237.32

755.86

166.67

94.76

Glenmark Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,647.6

92.293,95,254.452,000.460.977,107.14101.44

Divis Laboratories Ltd

DIVISLAB

6,493

78.031,72,374.066670.462,536561.08

Cipla Ltd

CIPLA

1,484

24.331,19,795.191,485.41.084,254.47397.41

Dr Reddys Laboratories Ltd

DRREDDY

1,326.1

20.691,10,689.831,200.70.65,546.3345.79

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,164

56.271,07,213.014741.012,385224.33

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glenmark Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Glenn Saldanha

Executive Director (Corporate)

Cheryl Pinto

Non Executive Director

B E Saldanha

Independent Non Exe. Director

Rajesh Desai.

Independent Non Exe. Director

Sona Saira Ramasastry

Independent Non Exe. Director

Dipankar Bhattacharjee

Independent Non Exe. Director

V R Iyer

Additional Director

Pradeep Kumar Sinha

Additional Director & WTD & ED

Anurag Mantri

Registered Office

B/2 Mahalaxmi Chambers,

22 Bhulabhai Desai Road,

Maharashtra - 400026

Tel: 91-22-40189999

Website: http://www.glenmarkpharma.com

Email: complianceofficer@glenmarkpharma.com

Registrar Office

Karvy Selenium Tow-B,

31&32 Financial Dist, Nanakramguda,

Hyderabad-500032

Tel: 91-40-67162222

Website: www.kfintech.com

Email: einward.ris@kfintech.com

Summary

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological enti...
Read More

Company FAQs

What is the Glenmark Pharmaceuticals Ltd share price today?

The Glenmark Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1636.7 today.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd is ₹46187.81 Cr. as of 20 Jun ‘25

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

The PE and PB ratios of Glenmark Pharmaceuticals Ltd is 26.48 and 1.89 as of 20 Jun ‘25

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

The 52-week high/low is the highest and lowest price at which a Glenmark Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Pharmaceuticals Ltd is ₹1199.3 and ₹1830.95 as of 20 Jun ‘25

What is the CAGR of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's CAGR for 5 Years at 31.98%, 3 Years at 66.92%, 1 Year at 32.65%, 6 Month at 6.39%, 3 Month at 10.26% and 1 Month at 13.95%.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?

The shareholding pattern of Glenmark Pharmaceuticals Ltd is as follows:
Promoters - 46.65 %
Institutions - 37.80 %
Public - 15.56 %
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.